<?xml version="1.0" encoding="UTF-8" ?>
<?xml-stylesheet type="text/xsl" href="http://socialize.morningstar.com/NewSocialize/utility/FeedStylesheets/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Guru Stok Picks</title><link>http://socialize.morningstar.com/NewSocialize/blogs/Pikeman/default.aspx</link><description>This is a blog to elaborate on stock picks based on criteria and investment style of well known market gurus like Peter Lynch, Warren Buffett, Martin Zweig, etc.</description><dc:language>en</dc:language><generator>CommunityServer 2.1 (Build: 60809.935)</generator><item><title>Stock Picks Peter Lynch would like for 2008</title><link>http://socialize.morningstar.com/NewSocialize/blogs/Pikeman/archive/2008/01/14/Stock-Picks-Peter-Lynch-would-like-for-2008.aspx</link><pubDate>Mon, 14 Jan 2008 10:14:14 GMT</pubDate><guid isPermaLink="false">30c6ca6e-72d0-4918-b5f9-d2ac565bc50b:2476149</guid><dc:creator>Pikeman</dc:creator><slash:comments>2</slash:comments><comments>http://socialize.morningstar.com/NewSocialize/blogs/Pikeman/comments/2476149.aspx</comments><wfw:commentRss>http://socialize.morningstar.com/NewSocialize/blogs/Pikeman/commentrss.aspx?PostID=2476149</wfw:commentRss><description>&lt;p&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Verdana;"&gt;Today I will talk about a global medical specialty company &lt;/span&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Tahoma;"&gt;&lt;a href="http://www2.barchart.com/profile.asp?sym=ACL&amp;amp;code=BCSPKS" title="ACL" target="_blank"&gt;&lt;font color="#800080"&gt;ACL&lt;/font&gt;&lt;/a&gt;&lt;/span&gt;&lt;span style="font-size:8pt;color:black;font-family:Tahoma;"&gt;&amp;nbsp;&lt;/span&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Tahoma;"&gt; &amp;ndash; &lt;/span&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Verdana;"&gt;Alcon, Inc., that &lt;a href="http://www.coolstockpicks.com/gurus/Peter%20Lynch.html" title="Lynch" target="_blank"&gt;&lt;font color="#800080"&gt;Peter Lynch&lt;/font&gt;&lt;/a&gt; would like to consider for his portfolio. This company could outperform the S&amp;amp;P 500 index in 2008.&lt;/span&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Tahoma;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Verdana;"&gt;The specialty drug market is a good defensive move in a slowing economy, with generic drugs in particular remaining a solid investment regardless of which party wins presidential election.&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Verdana;"&gt;&amp;nbsp;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Verdana;"&gt;ACL - Alcon, Inc. (Alcon)&lt;/span&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Tahoma;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Verdana;"&gt;is a research and development driven, global medical specialty company focused on eye care. The Company develops, manufactures and markets pharmaceuticals, surgical equipment and devices and consumer eye care products to treat diseases and disorders of the eye. &lt;/span&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Tahoma;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;color:black;font-family:Verdana;"&gt;&amp;nbsp;&lt;/span&gt;&lt;span style="color:#333333;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Verdana;"&gt;Lynch&lt;span class="normalloose1"&gt;&lt;span&gt; looks for consistently profitable, out-of-the-limelight, low-debt, reasonably priced stocks meeting his earnings growth requirements. Although in Lynch&amp;#39;s view: stocks growing earnings faster than 30% annually are risky bets and high growth rates aren&amp;#39;t sustainable, ACL&amp;rsquo;s &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:8pt;color:black;font-family:Verdana;"&gt;Annual EPS Growth Rate is 33,7% and in my opinion ACL under current conditions is still a good candidate for Lynch&amp;rsquo;s 2008 portfolio. &lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="color:#333333;"&gt;&lt;font face="Times New Roman" size="3"&gt;&amp;nbsp;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;table cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;"&gt;&lt;tr&gt;&lt;td style="padding-right:5.4pt;padding-left:5.4pt;padding-bottom:0cm;width:213.05pt;padding-top:0cm;background-color:transparent;border:#ece9d8;"&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;strong&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;ACL&amp;rsquo;s fundamentals:&lt;/span&gt;&lt;/strong&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;strong&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;Annual EPS Growth Rate &amp;ndash; 33,70%&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;Debt to Equity Ratio &amp;ndash; 0,28&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;Current P/E Ratio &amp;ndash; 28,9&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;% Institutional Ownership &amp;ndash; 19,10%&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;Pre-Tax Margin: 5-Year Avg. &amp;ndash; 28.00%&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;&amp;nbsp;&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Verdana;"&gt;Earnings Growth Estimates 2008 - +16,40%&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;&amp;nbsp;&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-right:5.4pt;padding-left:5.4pt;padding-bottom:0cm;width:213.05pt;padding-top:0cm;background-color:transparent;border:#ece9d8;"&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;strong&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;ACL&amp;rsquo;s technical analysis opinion:&lt;/span&gt;&lt;/strong&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;strong&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;em&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;Short Term Indicators:&lt;/span&gt;&lt;/em&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;7 Day Average Directional Indicator - BUY&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;20 - 50 Day MACD Oscillator - BUY&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;&amp;nbsp;&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;em&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;Long Term Indicators:&lt;/span&gt;&lt;/em&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;100 Day Moving Average vs Price - BUY&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;50 - 100 Day MACD Oscillator - BUY&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span style="font-size:8pt;font-family:Verdana;"&gt;&amp;nbsp;&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/p&gt;&lt;p&gt;&lt;font face="Verdana"&gt;&lt;span class="normalloose1"&gt;&lt;span style="font-size:8pt;color:#333333;"&gt;I have no idea how Peter Lynch would react to this stock pick that I think he would like. But one thing&amp;#39;s for sure: he would not buy this stock without doing extensive due diligence and becoming thoroughly familiar with it. And neither should you. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:8pt;color:black;font-family:Verdana;"&gt;So have fun, and get your stuff done.&lt;/span&gt;&lt;/font&gt;&lt;span style="font-size:8pt;color:#333333;font-family:Tahoma;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNormal" style="margin:0cm 0cm 0pt;"&gt;&lt;span&gt;&lt;font face="Times New Roman" size="3"&gt;&amp;nbsp;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;img src="http://socialize.morningstar.com/NewSocialize/aggbug.aspx?PostID=2476149" width="1" height="1"&gt;</description></item></channel></rss>